Company: MIRA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010301
Chunk: 11

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 11
---
 2024 
     1,763,570  
    $3.88  
     4.4  
     - 

    Outstanding as December 31, 2024 
     1,763,570  
    $3.88  
     3.6  
     - 
  
    Granted 
     -  
    $-  
     -  
     - 
  
    Outstanding as March 31, 2025 
     1,763,570  
    $3.88  
     3.4  
     - 
  
    Exercisable, March 31, 2025 
     1,763,570  
    $3.88  
     3.4  
     - 

     11 

MIRA PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024

(Unaudited)

Note
6. Segment Information

The
Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neurologic and
neuropsychiatric disorders. The Chief Operating Decision Maker for the Company is the CEO. The Company’s CEO reviews operating
results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance
and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The
CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a basis
for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

The
accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies
within Note 1 herein and in the 2024 Annual Report. The CEO assesses performance for the Company and decides how to allocate resources
based on the aggregate net loss that is also reported on the income statement as net loss. The measure of segment assets is reported
on the balance sheets as total assets.

The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

Schedule
of segment expenses and other segment expenses 

    2025  
    2024 

    Three Months Ended March 31,